CYTK · Cytokinetics Inc
Market Cap
$10.94B
Shares
139.02M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$88.04M
+376.6%
FY2025
Net Income
-$784.96M
-33.2%
FY2025
Operating Margin
-695.44%
+2207.3pp
FY2025
Diluted EPS
-$6.54
-24.3%
FY2025
Operating Cash Flow
-$510.01M
-28.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $67.67M | $88.04M | $18.47M | $7.53MG | $94.59M | $70.43M | $55.83M | $26.87M | $31.5M | $13.37M | $106.41M | $28.66M | $46.94M | $30.65M | $7.56M | $4M | $2.58M | $81.54M | — | — | — | — | — | — | — | — | |
| $400.96M | $416.03M | $339.41M | $330.12M | $240.81M | $159.94M | $96.95M | $86.13M | $89.14M | $90.3M | $59.9M | $46.4M | $44.43M | $49.45M | $35.64M | $37.18M | $38.01M | $39.84M | — | — | — | — | — | — | — | — | |
| — | $284.27M | $215.31M | $173.61M | $177.98M | $96.8M | $52.82M | $39.61M | $31.28M | $36.47M | $27.82M | $19.67M | $17.27M | $15.09M | $12.43M | $13.59M | $14.2M | $15.63M | — | — | — | — | — | — | — | — | |
| $12.55M | $10.13M | $9.53M | $11.89M | $5.81M | $2.28M | $1.83M | $1.29M | $1.24M | $1.92M | $741K | $589K | $490K | $433K | $591K | $1.3M | $1.9M | $2.02M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$56K | $1.19M | — | -$23K | — | — | — | — | — | — | — | — | |
| $775.58M | $700.3M | $554.72M | $503.74M | $418.79M | $256.74M | $149.77M | $125.74M | $120.42M | $126.76M | $87.72M | $66.07M | $61.69M | $64.54M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $59.2M | — | — | — | — | — | — | — | — | — | — | — | $61.69M | $64.54M | $48.02M | $51.96M | $52.21M | $55.44M | — | — | — | — | — | — | — | — | |
| -$707.91M | -$612.26M | -$536.25M | -$496.21M | -$324.2M | -$186.31M | -$93.94M | -$98.87M | -$88.92M | -$113.4M | $18.69M | -$37.41M | -$14.75M | -$33.89M | -$40.46M | -$47.96M | -$49.64M | $26.1M | — | — | — | — | — | — | — | — | |
| — | -695.44% | -2902.72% | -6589.71% | -342.75% | -264.54% | -168.27% | -367.97% | -282.26% | -848.26% | 17.56% | -130.53% | -31.43% | -110.59% | -535.22% | -1199.1% | -1926.08% | 32% | — | — | — | — | — | — | — | — | |
| -$695.36M | -$602.13M | -$526.72M | -$484.31M | -$318.39M | -$184.04M | -$92.11M | -$97.57M | -$87.68M | -$111.48M | $19.43M | -$36.82M | -$14.26M | -$33.46M | -$39.87M | -$46.67M | -$47.74M | $28.12M | — | — | — | — | — | — | — | — | |
| — | $45.58M | $37.7M | $28.31M | $19.41M | $16.44M | $15.96M | $6.62M | $3.8M | $3.02M | $2.7M | $268K | $0 | $0 | $3000 | $35K | $176K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $11.4M | $1M | $5.3M | $4.5M | $4.2M | — | $449K | $156K | $101K | $96K | $83K | $132K | $318K | — | — | — | — | — | — | — | — | — | |
| $46.68M | $48.42M | $51.53M | $27.63M | $11.34M | $331K | $5.33M | $4.54M | $4.19M | $2.6M | $464K | $174K | $108K | $177K | $87K | $104K | $172K | -$1.4M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | -$106.29M | -$127.79M | $16.45M | -$37.5M | -$14.65M | -$33.72M | -$40.37M | -$47.86M | -$49.46M | $24.69M | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$176K | $150K | — | — | — | — | — | — | — | — | |
| -$894M | -$784.96M | -$589.53M | -$526.24M | -$388.96M | -$215.31M | -$127.29M | -$121.69M | -$106.29M | -$127.79M | $16.45M | -$37.5M | -$14.65M | -$33.72M | -$40.37M | -$47.86M | -$49.29M | $24.54M | -$56.37M | -$48.89M | -$57.12M | -$42.25M | -$37.2M | -$32.69M | -$23.08M | -$15.87M | |
| — | -891.6% | -3191.11% | -6988.63% | -411.21% | -305.72% | -228% | -452.93% | -337.41% | -955.94% | 15.46% | -130.86% | -31.2% | -110.01% | -534.07% | -1196.5% | -1912.57% | 30.1% | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$14.65M | -$33.72M | -$41.68M | -$50.72M | -$49.29M | $24.54M | — | — | — | — | — | — | — | — | |
| -$897.67M | -$786.72M | -$587.12M | -$522.66M | -$391.68M | -$216.33M | -$127.82M | -$121.51M | -$106.13M | -$127.58M | $16.44M | -$37.35M | -$14.66M | -$33.73M | -$40.36M | -$47.85M | -$49.29M | $24.53M | -$56.36M | -$48.82M | -$57.18M | -$42.08M | -$37.43M | -$32.68M | -$23.31M | -$15.68M | |
| USD/shares | -$7.23 | -$6.54 | -$5.26 | -$5.45 | -$4.33 | -$2.80 | -$1.97 | — | — | -$2.59 | $0.41 | -$0.97 | -$0.41 | — | — | -$0.72 | -$0.77 | $0.43 | — | — | — | — | — | — | — | — |
| USD/shares | -$7.23 | -$6.54 | -$5.26 | -$5.45 | -$4.33 | -$2.80 | -$1.97 | — | — | -$2.59 | $0.39 | -$0.97 | -$0.41 | — | — | -$0.72 | -$0.77 | $0.42 | — | — | — | — | — | — | — | — |
| shares | — | 120.1K | 111.98K | 96.52K | 89.83K | 76.89K | 64.52K | 57.58K | 54.42K | 49.4M | 39.94M | 38.81M | 35.71M | 27.28M | 108.64M | 70.8M | 64.29M | 57.39M | — | — | — | — | — | — | — | — |
| shares | — | 120.1K | 111.98K | 96.52K | 89.83K | 76.89K | 64.52K | 57.58K | 54.42K | 49.4M | 42.56M | 38.81M | 35.71M | 27.28M | 18.11M | 70.8M | 64.17M | 57.96M | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Showing the latest 26 of 27 periods — chart a line item for full history.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
173.14×
Peer median 10.78×
EV/EBIT
—
Peer median 34.80×
P/E (TTM)
—
Peer median 19.92×
Peer medians compare against the 137 similar-size Biotechnology companies (of 524 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| China | $600,000 | $3,300,000 | $1,300,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| License and Milestone Revenues | $79,353,000 | $15,000,000 | $3,500,000 | $1,000,000 | $54,900,000 | — | — | — |
| Collaboration Revenues | $8,686,000 | $3,474,000 | $4,030,000 | $6,588,000 | — | — | — | — |
| Milestone | — | — | — | — | $5,000,000 | $2,800,000 | $0 | $0 |
| Realization Of Revenue Participation Right Purchase Agreement | — | — | — | $87,000,000 | $0 | $0 | — | — |
| Research And Development | — | — | — | — | $10,572,000 | $16,527,000 | $26,868,000 | $26,368,000 |
| License | — | — | — | — | $54,900,000 | $36,501,000 | $0 | $5,133,000 |
Key facts
CIK
1061983
CUSIP
23282W605
13F (30d)
393 filings
389 filers
Visit website
Investor relations